Clinical Report: Discovery of the uncommon H3-3A p.G35W mutation in an adolescent
Overview
This case study presents an adolescent with a tectal plate lesion diagnosed as a pilocytic astrocytoma, where a rare H3-3A p.G35W mutation was identified. The findings underscore the importance of molecular profiling in understanding tumor behavior and guiding treatment in pediatric low-grade gliomas.
Background
Tectal plate gliomas are rare pediatric tumors that often present with obstructive hydrocephalus due to their location. Recent advancements in molecular diagnostics have highlighted the significance of specific mutations, such as those in the H3-3A gene, in determining tumor characteristics and potential treatment pathways. Understanding these mutations is crucial for optimizing management strategies in pediatric gliomas.
Data Highlights
No numerical data available in the article.
Key Findings
The patient underwent a stereotactic endoscopic biopsy, revealing a pilocytic astrocytoma.
A rare H3-3A p.G35W mutation was identified, not previously characterized in tectal plate gliomas.
Methylation profiling was performed to better understand the tumor's molecular characteristics.
The H3-3A p.G35W variant has been primarily associated with giant cell tumors of the bone.
Current WHO classifications recognize distinct tumor types based on molecular features, impacting treatment decisions.
Clinical Implications
Molecular profiling, including methylation analysis, is essential in the management of pediatric low-grade gliomas to inform treatment decisions. The identification of specific mutations can guide targeted therapies and improve patient outcomes.
Conclusion
This case highlights the need for comprehensive molecular diagnostics in pediatric gliomas, particularly in rare mutations that may influence tumor behavior and treatment strategies.
by Andy Ung, Vanesa M. Tomatis, Esther Quick, Laveniya Satgunaseelan, Ema Knight, Chrisovalantis Tsimiklis, Elyse C Page, Jordan R. Hansford, Annika R. Mascarenhas
US claims data showed rising prevalence of diabetic retinal disease in type 1 and type 2 diabetes, while incidence declined in type 1 diabetes and moved closer to type 2 rates by 2022.
